Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance.

Authors:
Clarence Hale
Clarence Hale
One Amgen Center Drive
Michelle M Chen
Michelle M Chen
Yale University School of Medicine
United States
Narumol Chinookoswong
Narumol Chinookoswong
One Amgen Center Dr.
Thousand Oaks | United States
Todd Hager
Todd Hager
Department of Pharmacokinetics and Drug Metabolism
Minghan Wang
Minghan Wang
University of British Columbia
Canada
Jing Xu
Jing Xu
State Key Laboratory of Medicinal Chemical Biology
China

Endocrinology 2012 Jan 8;153(1):69-80. Epub 2011 Nov 8.

Department of Metabolic Disorders, Amgen Inc., MS 29-1-A, One Amgen Center Drive, Thousand Oaks, California 91320, USA.

Circulating levels of fibroblast growth factor 21 (FGF21), a metabolic regulator of glucose, lipid, and energy homeostasis, are elevated in obese diabetic subjects, raising questions about potential FGF21 resistance. Here we report tissue expression changes in FGF21 and its receptor components, and we describe the target-organ and whole-body responses to FGF21 in ob/ob and diet-induced obese (DIO) mice. Plasma FGF21 concentrations were elevated 8- and 16-fold in DIO and ob/ob mice, respectively, paralleling a dramatic increase in hepatic FGF21 mRNA expression. Concurrently, expression levels of βKlotho, FGF receptor (FGFR)-1c, and FGFR2c were markedly down-regulated in the white adipose tissues (WAT) of ob/ob and DIO mice. However, dose-response curves of recombinant human FGF21 (rhFGF21) stimulation of ERK phosphorylation in the liver and WAT were not right shifted in disease models, although the magnitude of induction in ERK phosphorylation was partially attenuated in DIO mice. Whole-body metabolic responses were preserved in ob/ob and DIO mice, with disease models being more sensitive and responsive than lean mice to the glucose-lowering and weight-loss effects of rhFGF21. Endogenous FGF21 levels, although elevated in diseased mice, were below the half-maximal effective concentrations of rhFGF21, suggesting a state of relative deficiency. Hepatic and WAT FGF21 mRNA expression levels declined after rhFGF21 treatment in the absence of the increased expression levels of βKlotho and FGFR. We conclude that overt FGF21 resistance was not evident in the disease models, and increased hepatic FGF21 expression as a result of local metabolic changes is likely a major cause of elevated circulating FGF21 levels.

Download full-text PDF

Source
http://dx.doi.org/10.1210/en.2010-1262DOI Listing
January 2012
7 Reads

Publication Analysis

Top Keywords

dio mice
16
fgf21
13
disease models
12
expression levels
12
fgf21 resistance
12
ob/ob dio
8
fgf21 levels
8
erk phosphorylation
8
levels βklotho
8
fgf21 mrna
8
overt fgf21
8
hepatic fgf21
8
mrna expression
8
mice
7
expression
6
levels
6
dio
5
shifted disease
4
phosphorylation liver
4
liver wat
4

Similar Publications

Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects.

Am J Physiol Endocrinol Metab 2009 Nov 25;297(5):E1105-14. Epub 2009 Aug 25.

Amgen Inc., MS 29-1-A, One Amgen Center Dr., Thousand Oaks, CA 91320, USA.

Recombinant fibroblast growth factor (FGF)21 has antihyperglycemic, antihyperlipidemic, and antiobesity effects in diabetic rodent and monkey models. Previous studies were confined to measuring steady-state effects of FGF21 following subchronic or chronic administration. The present study focuses on the kinetics of biological actions of FGF21 following a single injection and on the associated physiological and cellular mechanisms underlying FGF21 actions. Read More

View Article
November 2009

Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice.

Proc Natl Acad Sci U S A 2009 Aug 12;106(34):14379-84. Epub 2009 Aug 12.

Amgen Inc, South San Francisco, CA 94080, USA.

FGF19 is a hormone that regulates bile acid and glucose homeostasis. Progress has been made in identifying cofactors for receptor activation. However, several functions of FGF19 have not yet been fully defined, including the actions of FGF19 on target tissues, its FGF receptor specificity, and the contributions of other cofactors, such as heparin. Read More

View Article
August 2009

Increased fibroblast growth factor 21 expression in high-fat diet-sensitive non-human primates (Macaca mulatta).

Int J Obes (Lond) 2014 Feb 21;38(2):183-91. Epub 2013 May 21.

Department of Diabetes NBEs and Obesity Biology, Novo Nordisk A/S, Måløv, Denmark.

Objective: Fibroblast growth factor 21 (FGF21) is a metabolic regulator of glucose and lipid metabolism. The physiological role of FGF21 is not yet fully elucidated, however, administration of FGF21 lowers blood glucose in diabetic animals. Moreover, increased levels of FGF21 are found in obese and diabetic rodents and humans compared with lean/non-diabetic controls. Read More

View Article
February 2014

Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice.

Diabetes 2009 Jan 7;58(1):250-9. Epub 2008 Oct 7.

Department of Metabolic Disorders, Amgen, Thousand Oaks, California, USA.

Objective: Fibroblast growth factor 21 (FGF21) has emerged as an important metabolic regulator of glucose and lipid metabolism. The aims of the current study are to evaluate the role of FGF21 in energy metabolism and to provide mechanistic insights into its glucose and lipid-lowering effects in a high-fat diet-induced obesity (DIO) model.

Research Design And Methods: DIO or normal lean mice were treated with vehicle or recombinant murine FGF21. Read More

View Article
January 2009